he challenged composition claims cover two “iso-
lated” human genes, BRCA1 and BRCA2 (collectively,
“BRCA1/2” or “BRCA”), and certain alterations, or muta-
tions, in these genes associated with a predisposition to
breast and ovarian cancers. Representative composition
claims include claims 1, 2, and 5 of the ’282 patent:

1. An isolated DNA coding for a BRCA1 polypep-
tide, said polypeptide having the amino acid se-
quence set forth in SEQ ID NO:2.

2. The isolated DNA of claim 1, wherein said
DNA has the nucleotide sequence set forth in SEQ
ID NO:1.

5. An isolated DNA having at least 15 nucleotides
of the DNA of claim 1.